ENTrigue Surgical, Inc. ("ENTrigue" or the "Company"), a privately held company that develops, manufactures and distributes medical devices used for Ear, Nose and Throat surgical procedures, announced today the limited commercial release in the United States of its Ventera®-R Sinus Dilation System for revision surgery of the frontal, maxillary and sphenoid sinuses. The Ventera-R Sinus Dilation System utilizes a single-use balloon delivered by a re-usable instrument based on the Company's proprietary SerpENT® articulating instrument technology and does not require either manual tip shaping or the use of a guide wire or cannula for positioning the dilation balloon.
Amin Javer, M.D., a world renowned Rhinologist and Director of St. Paul's Sinus Center in Vancouver, Canada, remarked, "We have used the Ventera Sinus Dilation System for revision surgery of the sinuses and have found that it is a cost-effective tool to manage revision surgery patients in both the office and operating room settings."
Sinusitis, or inflammation of one or more of the paranasal sinuses, often requires surgical treatment to clear obstructions and restore air flow. Revision, or repeat, surgery may be required if symptoms recur. Fred Dinger, ENTrigue President and CEO, commented, "We believe that the unique abilities of the Ventera-R System to articulate and lock into position within the nasal passageways will address the variable anatomy encountered during revision sinus surgery."
ENTrigue Surgical, based in San Antonio, Texas, previously launched other balloon dilation systems based on the Ventera platform in Canada, certain European countries and South Africa. The Company recently announced a collaboration with fiagon GmbH to explore the development of a system for ENT surgeons that will combine navigation with one or more products of its Ventera Sinus Dilation platform.
Other products offered by ENTrigue in the U.S. include the SerpENT® Articulating Instruments; the ENTact® Septal Stapler that delivers bioabsorbable implants for the closure of mucosal flaps during a septoplasty procedure; and the Synero® Hemostatic Gel, a surface-acting, mucosal bleeding control product that allows the nasal passages to remain open post-operatively from sinus surgery. In addition to these products, the Company offers in selected international markets the MediENT® Middle Turbinate Implant, a bioabsorbable device for the post-operative management of middle turbinate lateralization. For more information about ENTrigue Surgical, Inc. and its products, please visit www.entriguesurgical.com.